Literature DB >> 31922346

Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States.

Jinoos Yazdany1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31922346      PMCID： PMC7255927          DOI： 10.1002/art.41203

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  5 in total

1.  How logically impossible patents block biosimilars.

Authors:  W Nicholson Price; Arti K Rai
Journal:  Nat Biotechnol       Date:  2019-08       Impact factor: 54.908

2.  Obstacles to the Adoption of Biosimilars for Chronic Diseases.

Authors:  Aaron Hakim; Joseph S Ross
Journal:  JAMA       Date:  2017-06-06       Impact factor: 56.272

3.  Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.

Authors:  Jinoos Yazdany; R Adams Dudley; Grace A Lin; Randi Chen; Chien-Wen Tseng
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

4.  Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.

Authors:  Hillel P Cohen; Andrew Blauvelt; Robert M Rifkin; Silvio Danese; Sameer B Gokhale; Gillian Woollett
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

5.  Academic oncology clinicians' understanding of biosimilars and information needed before prescribing.

Authors:  John W Cook; Megan K McGrath; Margie D Dixon; Jeffrey M Switchenko; R Donald Harvey; Rebecca D Pentz
Journal:  Ther Adv Med Oncol       Date:  2019-01-06       Impact factor: 8.168
  5 in total
  3 in total

1.  The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.

Authors:  Cosimo Bruni; Stefano Gentileschi; Giovanni Pacini; Caterina Baldi; Marco Capassoni; Lorenzo Tofani; Marco Bardelli; Laura Cometi; Luca Cantarini; Francesca Nacci; Michele Vietri; Francesca Bartoli; Ginevra Fiori; Bruno Frediani; Marco Matucci-Cerinic
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-13       Impact factor: 5.346

Review 2.  Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients.

Authors:  Hala Najeeb; Farah Yasmin; Salim Surani
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

Review 3.  Developments and opportunities in continuous biopharmaceutical manufacturing.

Authors:  Ohnmar Khanal; Abraham M Lenhoff
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.